Plus therapeutics provides highlights regarding leptomeningeal metastases acquisition and topline clinical trial data on the foresee trial

Company acquired assets for the synergistic leptomeningeal metastases (lm) diagnostic platform, “cnside™ ” and discussed potential partnering opportunities cnside can significantly improve lm diagnostic accuracy and the market size for plus' lead lm radiotherapeutic candidate rhenium (re186) obisbemeda company summarized topline data from the foresee clinical trial planned for complete presentation at the sno/asco meeting in august 2024 call replay & transcript available via the link below austin, texas, may 09, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “cnside” and topline data from the foresee clinical trial. “leptomeningeal metastases (lm) is significantly underdiagnosed because current tests such as mri and cytology lack sensitivity,” said priya u.
PSTV Ratings Summary
PSTV Quant Ranking